PI
RNAM

PEAK6 Investments’s Avidity Biosciences RNAM Stock Holding History

PEAK6 Investments’s Portfolio RNAM Stock Details RNAM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		$337K Buy
7,343
+343
+5% +$14.9K ﹤0.01% 2534
2024
Q2 		$286K Buy
+7,000
New +$201K ﹤0.01% 2575

Other funds holding RNAM

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

PEAK6 Investments's RNAM Position: Q3 2024 in Review

PEAK6 Investments increased its Avidity Biosciences (RNAM) stake by 4.9% in Q3 2024, buying an estimated $14.9K and bringing the position to 7,343 shares worth $337K. The position accounts for ﹤0.01% of the portfolio, ranked #2534.

PEAK6 Investments first reported a position in RNAM in Q2 2024 and has held it in 2 quarters since. 245 funds tracked by Wall St. Rank hold RNAM as of Q3 2024.

  • PEAK6 Investments held 7,343 shares of Avidity Biosciences worth $337K as of Q3 2024.
  • PEAK6 Investments bought 343 Avidity Biosciences shares in Q3 2024, an estimated $14.9K.
  • Avidity Biosciences made up ﹤0.01% of PEAK6 Investments's portfolio in Q3 2024, its #2534 holding.
  • PEAK6 Investments first reported a position in Avidity Biosciences in Q2 2024 and has held it in 2 quarters since.
  • 245 funds tracked by Wall St. Rank held Avidity Biosciences as of Q3 2024.

Based on PEAK6 Investments's 13F filing for Q3 2024, filed 14 Nov 2024.